-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, May 31.
Recently, the official website of the State Food and Drug Administration showed that Zhejiang Zuoli Pharmaceutical's esomeprazole sodium for injection was approved for production of imitation 6 categories.
According to data from Meinenet, the sales of terminal esomeprazole (esomeprazole) injections in Chinese public medical institutions will exceed 3 billion yuan in 2020.
There are more than 30 manufacturers of this product, of which AstraZeneca has the largest market share.
Recently, the official website of the State Food and Drug Administration showed that Zhejiang Zuoli Pharmaceutical's esomeprazole sodium for injection was approved for production of imitation 6 categories.
According to data from Meinenet, the sales of terminal esomeprazole (esomeprazole) injections in Chinese public medical institutions will exceed 3 billion yuan in 2020.
There are more than 30 manufacturers of this product, of which AstraZeneca has the largest market share.
Esomeprazole is a single levorotatory isomer of omeprazole, which belongs to the proton pump inhibitor (PPI), which can effectively inhibit gastric acid secretion.
Compared with other proton pump inhibitor drugs, it has a rapid, long-lasting and stable inhibitory effect.
Features of less acidity and less adverse reactions .
Compared with other proton pump inhibitor drugs, it has a rapid, long-lasting and stable inhibitory effect.
Features of less acidity and less adverse reactions .
Sales of terminal esomeprazole (esomeprazole) injections in Chinese public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Minai.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal sales of esomeprazole (esomeprazole) injections exceed 30 100 million yuan.
The production company has AstraZeneca, Chia Tai Pharmaceutical Group, Jiangsu Aosai Kang Pharmaceutical, Long days of Pharmaceutical (Hubei), Yangtze River Pharmaceutical Group, more than 30, which AstraZeneca's largest market share.
It is worth mentioning that in recent years, with the efforts of domestic pharmaceutical companies, AstraZeneca's market share has gradually declined, from monopolizing the market in 2015 to 51% in 2019, and has fallen below 50% in 2020.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal sales of esomeprazole (esomeprazole) injections exceed 30 100 million yuan.
The production company has AstraZeneca, Chia Tai Pharmaceutical Group, Jiangsu Aosai Kang Pharmaceutical, Long days of Pharmaceutical (Hubei), Yangtze River Pharmaceutical Group, more than 30, which AstraZeneca's largest market share.
It is worth mentioning that in recent years, with the efforts of domestic pharmaceutical companies, AstraZeneca's market share has gradually declined, from monopolizing the market in 2015 to 51% in 2019, and has fallen below 50% in 2020.
At present, the product has been evaluated by 9 companies including Zhengda Tianqing Pharmaceutical Group, Jiangsu Aosaikang Pharmaceutical, Jiangsu Zhengda Fenghai Pharmaceutical, Liaoning Haisco Pharmaceuticals, and 8 Yichang Dongyang Sunshine Yangtze River Pharmaceuticals, Yangzijiang Pharmaceutical Group, etc.
The supplementary application for the consistency evaluation of the enterprise is under review and approval.
In addition, nearly 20 companies including Sichuan Pharmaceutical Preparations, Sinopharm Rongsheng Pharmaceutical, and Changchun Haiyue Pharmaceutical have submitted listing applications for review and approval.
Among them, 6 companies have submitted listing applications for generic 4 types, and they will be deemed to be the same after approval.
Overrated.
The supplementary application for the consistency evaluation of the enterprise is under review and approval.
In addition, nearly 20 companies including Sichuan Pharmaceutical Preparations, Sinopharm Rongsheng Pharmaceutical, and Changchun Haiyue Pharmaceutical have submitted listing applications for review and approval.
Among them, 6 companies have submitted listing applications for generic 4 types, and they will be deemed to be the same after approval.
Overrated.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network News, May 31.
Recently, the official website of the State Food and Drug Administration showed that Zhejiang Zuoli Pharmaceutical's esomeprazole sodium for injection was approved for production of imitation 6 categories.
According to data from Meinenet, the sales of terminal esomeprazole (esomeprazole) injections in Chinese public medical institutions will exceed 3 billion yuan in 2020.
There are more than 30 manufacturers of this product, of which AstraZeneca has the largest market share.
Recently, the official website of the State Food and Drug Administration showed that Zhejiang Zuoli Pharmaceutical's esomeprazole sodium for injection was approved for production of imitation 6 categories.
According to data from Meinenet, the sales of terminal esomeprazole (esomeprazole) injections in Chinese public medical institutions will exceed 3 billion yuan in 2020.
There are more than 30 manufacturers of this product, of which AstraZeneca has the largest market share.
Esomeprazole is a single levorotatory isomer of omeprazole, which belongs to the proton pump inhibitor (PPI), which can effectively inhibit gastric acid secretion.
Compared with other proton pump inhibitor drugs, it has a rapid, long-lasting and stable inhibitory effect.
Features of less acidity and less adverse reactions .
Compared with other proton pump inhibitor drugs, it has a rapid, long-lasting and stable inhibitory effect.
Features of less acidity and less adverse reactions .
Sales of terminal esomeprazole (esomeprazole) injections in Chinese public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Minai.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal sales of esomeprazole (esomeprazole) injections exceed 30 100 million yuan.
The production company has AstraZeneca, Chia Tai Pharmaceutical Group, Jiangsu Aosai Kang Pharmaceutical, Long days of Pharmaceutical (Hubei), Yangtze River Pharmaceutical Group, more than 30, which AstraZeneca's largest market share.
It is worth mentioning that in recent years, with the efforts of domestic pharmaceutical companies, AstraZeneca's market share has gradually declined, from monopolizing the market in 2015 to 51% in 2019, and has fallen below 50% in 2020.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal sales of esomeprazole (esomeprazole) injections exceed 30 100 million yuan.
The production company has AstraZeneca, Chia Tai Pharmaceutical Group, Jiangsu Aosai Kang Pharmaceutical, Long days of Pharmaceutical (Hubei), Yangtze River Pharmaceutical Group, more than 30, which AstraZeneca's largest market share.
It is worth mentioning that in recent years, with the efforts of domestic pharmaceutical companies, AstraZeneca's market share has gradually declined, from monopolizing the market in 2015 to 51% in 2019, and has fallen below 50% in 2020.
At present, the product has been evaluated by 9 companies including Zhengda Tianqing Pharmaceutical Group, Jiangsu Aosaikang Pharmaceutical, Jiangsu Zhengda Fenghai Pharmaceutical, Liaoning Haisco Pharmaceuticals, and 8 Yichang Dongyang Sunshine Yangtze River Pharmaceuticals, Yangzijiang Pharmaceutical Group, etc.
The supplementary application for the consistency evaluation of the enterprise is under review and approval.
In addition, nearly 20 companies including Sichuan Pharmaceutical Preparations, Sinopharm Rongsheng Pharmaceutical, and Changchun Haiyue Pharmaceutical have submitted listing applications for review and approval.
Among them, 6 companies have submitted listing applications for generic 4 types, and they will be deemed to be the same after approval.
Overrated.
The supplementary application for the consistency evaluation of the enterprise is under review and approval.
In addition, nearly 20 companies including Sichuan Pharmaceutical Preparations, Sinopharm Rongsheng Pharmaceutical, and Changchun Haiyue Pharmaceutical have submitted listing applications for review and approval.
Among them, 6 companies have submitted listing applications for generic 4 types, and they will be deemed to be the same after approval.
Overrated.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network News, May 31.
Recently, the official website of the State Food and Drug Administration showed that Zhejiang Zuoli Pharmaceutical's esomeprazole sodium for injection was approved for production of imitation 6 categories.
According to data from Meinenet, the sales of terminal esomeprazole (esomeprazole) injections in Chinese public medical institutions will exceed 3 billion yuan in 2020.
There are more than 30 manufacturers of this product, of which AstraZeneca has the largest market share.
Recently, the official website of the State Food and Drug Administration showed that Zhejiang Zuoli Pharmaceutical's esomeprazole sodium for injection was approved for production of imitation 6 categories.
According to data from Meinenet, the sales of terminal esomeprazole (esomeprazole) injections in Chinese public medical institutions will exceed 3 billion yuan in 2020.
There are more than 30 manufacturers of this product, of which AstraZeneca has the largest market share.
Esomeprazole is a single levorotatory isomer of omeprazole, which belongs to the proton pump inhibitor (PPI), which can effectively inhibit gastric acid secretion.
Compared with other proton pump inhibitor drugs, it has a rapid, long-lasting and stable inhibitory effect.
Features of less acidity and less adverse reactions .
Adverse reactions adverse reactions adverse reactionsCompared with other proton pump inhibitor drugs, it has a rapid, long-lasting and stable inhibitory effect.
Features of less acidity and less adverse reactions .
Sales of terminal esomeprazole (esomeprazole) injections in Chinese public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Minai.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal sales of esomeprazole (esomeprazole) injections exceed 30 100 million yuan.
The production company has AstraZeneca, Chia Tai Pharmaceutical Group, Jiangsu Aosai Kang Pharmaceutical, Long days of Pharmaceutical (Hubei), Yangtze River Pharmaceutical Group, more than 30, which AstraZeneca's largest market share.
It is worth mentioning that in recent years, with the efforts of domestic pharmaceutical companies, AstraZeneca's market share has gradually declined, from monopolizing the market in 2015 to 51% in 2019, and has fallen below 50% in 2020.
Hospital Hospital Hospital Enterprise Enterprise Enterprisecom, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal sales of esomeprazole (esomeprazole) injections exceed 30 100 million yuan.
The production company has AstraZeneca, Chia Tai Pharmaceutical Group, Jiangsu Aosai Kang Pharmaceutical, Long days of Pharmaceutical (Hubei), Yangtze River Pharmaceutical Group, more than 30, which AstraZeneca's largest market share.
It is worth mentioning that in recent years, with the efforts of domestic pharmaceutical companies, AstraZeneca's market share has gradually declined, from monopolizing the market in 2015 to 51% in 2019, and has fallen below 50% in 2020.
At present, the product has been evaluated by 9 companies including Zhengda Tianqing Pharmaceutical Group, Jiangsu Aosaikang Pharmaceutical, Jiangsu Zhengda Fenghai Pharmaceutical, Liaoning Haisco Pharmaceuticals, and 8 Yichang Dongyang Sunshine Yangtze River Pharmaceuticals, Yangzijiang Pharmaceutical Group, etc.
The supplementary application for the consistency evaluation of the enterprise is under review and approval.
In addition, nearly 20 companies including Sichuan Pharmaceutical Preparations, Sinopharm Rongsheng Pharmaceutical, and Changchun Haiyue Pharmaceutical have submitted listing applications for review and approval.
Among them, 6 companies have submitted listing applications for generic 4 types, and they will be deemed to be the same after approval.
Overrated.
The supplementary application for the consistency evaluation of the enterprise is under review and approval.
In addition, nearly 20 companies including Sichuan Pharmaceutical Preparations, Sinopharm Rongsheng Pharmaceutical, and Changchun Haiyue Pharmaceutical have submitted listing applications for review and approval.
Among them, 6 companies have submitted listing applications for generic 4 types, and they will be deemed to be the same after approval.
Overrated.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
